Overview

GnRHa + Letrozole vs Diane-35 + Metformin in Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Status:
Not yet recruiting

Trial end date:
2025-03-30

Target enrollment:

Participant gender:

Summary

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Xiaojun Chen

Treatments:

Cyproterone
Cyproterone acetate, ethinyl estradiol drug combination
Ethinyl Estradiol
Letrozole